Economic Impact of COVID-19 Vaccination Programs on Healthcare Workers: A Comparative Model-Based Analysis in the US, UK, Japan, and the Netherlands
Author(s)
Sebestyén-Balogh O1, Van de Velde N2, Hagiwara Y3, Westra T4, Joshi K5, Boersma C6, Postma M7, Igarashi A8, Beck E9
1Moderna, UK, London, LON, UK, 2Moderna, Inc., Cambridge, MA, USA, 3Moderna, Inc., Japan, Japan, JA, Japan, 4Moderna, Inc., Netherlands, de Wijk, Netherlands, 5Moderna, Inc., Cambridge, MA, USA, Cambridge , MA, USA, 6University of Groningen, University Medical Center Groningen, Zeist, UT, Netherlands, 7University of Groningen, University Medical Center Groningen, Groningen, GR, Netherlands, 8M3, Inc., Japan, Tokyo, Japan, 9Moderna, Inc., Cambridge, MA, USA, Munich, BY, Germany
Presentation Documents
OBJECTIVES: Ensuring high vaccination coverage among healthcare workers (HCWs) is vital for protecting the workforce and maintaining healthcare operability, especially during periods of increased respiratory disease activity, thereby preventing system overload. This study analyses the economic impact of increased vaccination coverage compared to current rates among HCWs using a health economic model.
METHODS: The model estimates the clinical and economic impact of COVID-19 vaccination programs targeting 75% coverage among HCWs in the US, UK, Japan, and the Netherlands. It is a decision tree model assessing symptomatic infections, long COVID cases, hospitalisations, deaths, and absenteeism. Based on clinical outcomes corresponding productivity losses were estimated, utilising country-specific input data and coverage rates.
RESULTS: The model results indicate substantial savings for employers in all four countries through reduced COVID-19 absenteeism and improved workforce productivity. The benefits of increased vaccination rates were evaluated for 22.3 million HCWs in the US, 1.5 million HCWs in the UK, 9.4 million HCWs in Japan, and 1.2 million HCWs in the Netherlands. Prevention of 4 million sick days in the US translated to potential savings (US$) of $1 billion; 280,000 sick days in the UK resulted in $47 million in savings; 2.2 million sick days in Japan corresponded to $280 million in savings; and 100,000 sick days in the Netherlands equated to $20 million in savings. In a scenario analysis considering increased risk of infection (RR2.5) and severe long COVID (RR2.6), while maintaining 75% vaccination coverage, savings were estimated at $3.1 billion, $170 million, $980 million, and $57 million, respectively.
CONCLUSIONS: Increased vaccination coverage among HCWs leads to economic benefits, including reduced absenteeism and productivity losses. These findings underscore the critical importance of attaining high vaccination coverage among HCWs to enhance healthcare system resilience. Additionally, the results support recommendations for extending vaccination efforts to other high-risk groups.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE393
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines